Stock of the Day

April 14, 2021

Genmab A/S (GMAB)

$22.07
+$0.26 (+1.2%)
Market Cap: $14.15B

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S Bull Case

Here are some ways that investors could benefit from investing in Genmab A/S:

  • The current stock price is around $20.93, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Genmab A/S has recently reported earnings that exceeded analysts' expectations, indicating strong financial performance and potential for future growth.
  • The company has a solid market capitalization of approximately $13.42 billion, suggesting stability and the ability to invest in research and development.
  • Analysts have a consensus rating of "Moderate Buy" for Genmab A/S, with a price target suggesting significant upside potential from the current price.
  • Recent investments from institutional investors, including GTS Securities LLC, indicate growing confidence in the company's future prospects.

Genmab A/S Bear Case

Investors should be bearish about investing in Genmab A/S for these reasons:

  • The company has a relatively high price-to-earnings (P/E) ratio of around 12.03, which may suggest that the stock is overvalued compared to its earnings.
  • Despite recent positive earnings, the revenue reported was significantly lower than analysts' expectations, which could raise concerns about future performance.
  • One analyst has rated the stock with a sell rating, indicating some skepticism about its short-term prospects.
  • The stock has experienced volatility, with a 12-month high of $28.96 and a low of $17.24, which may deter risk-averse investors.
  • Hedge funds and institutional investors only own about 7.07% of the company's stock, suggesting limited institutional confidence compared to other biotech firms.
← Previous Stock of the DayNext Stock of the Day →

Recent News